Daniel L Hertz1, Travis J Dockter2, Daniel V Satele2, Charles L Loprinzi3, Jennifer Le-Rademacher2. 1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St., Room 2560C, Ann Arbor, MI, USA. DLHertz@med.umich.edu. 2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA. 3. Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Clinical guidelines recommend altering chemotherapy treatment by decreasing, delaying, or discontinuing dosing in patients who are experiencing chemotherapy-induced peripheral neuropathy. There are few data available on the clinical use of treatment alteration including the severity of CIPN at the time of treatment alteration. METHODS: This was a retrospective analysis of patients receiving oxaliplatin on the NCCTG N08CB trial. Neuropathy severity was assessed at each cycle by clinicians and patients. Patients were classified as (1) completed treatment without alteration, (2) dose reduction or delay due to neuropathy, (3) discontinuation due to neuropathy, (4) discontinuation for other toxicity, or (5) discontinuation for another reason (5). Comparisons focused primarily on patients with alteration due to neuropathy (groups 2 and/or 3) compared with patients who completed treatment without alteration (group 1). RESULTS: In 350 participants, 135 (39%) completed treatment without alteration, 70 (20%) had a dose reduction or delay due to neuropathy, and 35 (10%) discontinued early due to neuropathy. Clinician-assessed neuropathy severity was greater in patients at the time of dose reduction or delay compared with severity at the end of treatment in patients without alteration (p < 0.0001). Patient-reported neuropathy severity at cycle 4 was worse in patients who eventually had a reduction or delay as compared with patients who completed treatment without alteration (p = 0.017). CONCLUSIONS: Treatment alterations due to neuropathy are common in patients receiving oxaliplatin for colon cancer and are associated with clinician-assessed neuropathy severity. Rapid increases in patient-reported neuropathy severity indicate a potential need for monitoring and intervention. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT01099449 (NCCTG N08CB).
BACKGROUND: Clinical guidelines recommend altering chemotherapy treatment by decreasing, delaying, or discontinuing dosing in patients who are experiencing chemotherapy-induced peripheral neuropathy. There are few data available on the clinical use of treatment alteration including the severity of CIPN at the time of treatment alteration. METHODS: This was a retrospective analysis of patients receiving oxaliplatin on the NCCTG N08CB trial. Neuropathy severity was assessed at each cycle by clinicians and patients. Patients were classified as (1) completed treatment without alteration, (2) dose reduction or delay due to neuropathy, (3) discontinuation due to neuropathy, (4) discontinuation for other toxicity, or (5) discontinuation for another reason (5). Comparisons focused primarily on patients with alteration due to neuropathy (groups 2 and/or 3) compared with patients who completed treatment without alteration (group 1). RESULTS: In 350 participants, 135 (39%) completed treatment without alteration, 70 (20%) had a dose reduction or delay due to neuropathy, and 35 (10%) discontinued early due to neuropathy. Clinician-assessed neuropathy severity was greater in patients at the time of dose reduction or delay compared with severity at the end of treatment in patients without alteration (p < 0.0001). Patient-reported neuropathy severity at cycle 4 was worse in patients who eventually had a reduction or delay as compared with patients who completed treatment without alteration (p = 0.017). CONCLUSIONS: Treatment alterations due to neuropathy are common in patients receiving oxaliplatin for colon cancer and are associated with clinician-assessed neuropathy severity. Rapid increases in patient-reported neuropathy severity indicate a potential need for monitoring and intervention. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT01099449 (NCCTG N08CB).
Authors: Manish R Sharma; Shailly Mehrotra; Elizabeth Gray; Kehua Wu; William T Barry; Clifford Hudis; Eric P Winer; Alan P Lyss; Deborah L Toppmeyer; Alvaro Moreno-Aspitia; Thomas E Lad; Mario Velasco; Beth Overmoyer; Hope S Rugo; Mark J Ratain; Jogarao V Gobburu Journal: J Clin Pharmacol Date: 2019-12-04 Impact factor: 3.126
Authors: Antoinetta J M Beijers; Floortje Mols; Vivianne C G Tjan-Heijnen; Catharina G Faber; Lonneke V van de Poll-Franse; Gerard Vreugdenhil Journal: Acta Oncol Date: 2014-11-24 Impact factor: 4.089
Authors: Teresa M Salgado; Caroline S Quinn; Emily K Krumbach; Iris Wenceslao; Martha Gonzalez; Holly L Reed; Jillian G Syverson; Rebecca S Etz; Kiran Vangipuram; Melissa R Barker; N Lynn Henry; Karen B Farris; Daniel L Hertz Journal: Support Care Cancer Date: 2020-01-02 Impact factor: 3.603
Authors: Raafi Ali; Vickie E Baracos; Michael B Sawyer; Laurent Bianchi; Sarah Roberts; Eric Assenat; Caroline Mollevi; Pierre Senesse Journal: Cancer Med Date: 2016-01-27 Impact factor: 4.452
Authors: Timothy J Iveson; Rachel S Kerr; Mark P Saunders; Jim Cassidy; Niels Henrik Hollander; Josep Tabernero; Andrew Haydon; Bengt Glimelius; Andrea Harkin; Karen Allan; John McQueen; Claire Scudder; Kathleen Anne Boyd; Andrew Briggs; Ashita Waterston; Louise Medley; Charles Wilson; Richard Ellis; Sharadah Essapen; Amandeep S Dhadda; Mark Harrison; Stephen Falk; Sherif Raouf; Charlotte Rees; Rene K Olesen; David Propper; John Bridgewater; Ashraf Azzabi; David Farrugia; Andrew Webb; David Cunningham; Tamas Hickish; Andrew Weaver; Simon Gollins; Harpreet S Wasan; James Paul Journal: Lancet Oncol Date: 2018-04 Impact factor: 41.316
Authors: Sebastian W Nielsen; Sanne Lindberg; Christina Halgaard Bruvik Ruhlmann; Lise Eckhoff; Jørn Herrstedt Journal: J Clin Med Date: 2022-03-27 Impact factor: 4.241